2.5mg-7.5mg Mounjaro

What is Mounjaro?

Mounjaro (tirzepatide) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist developed by Eli Lilly. It represents a paradigm shift in metabolic treatment by simultaneously targeting two incretin pathways.

Mechanism of Action:

• GIP Receptor Activation: Enhances insulin secretion + inhibits glucagon only during hyperglycemia

• GLP-1 Effects: Slows gastric emptying (50% reduction vs placebo) + promotes satiety

• Adipose Tissue Modulation: Upregulates lipid storage genes, reducing visceral fat

FDA-Approved Indications

✅ Type 2 Diabetes (2022):

• HbA1c reduction: 1.8-2.4% (vs 1.4% for semaglutide in SURPASS-2 trial)

• 36% achieve HbA1c <5.7% (non-diabetic range)

✅ Chronic Weight Management (2023, as Zepbound brand):

• Average weight loss: 15-22% (SURMOUNT trials)

• 37% achieve ≥25% weight loss at highest dose

Dosage & Administration

Key Distinction:

• Flexible dosing: No rigid meal timing requirements

• Auto-injector: Hidden needle design reduces anxiety

We offer complimentary express shipping.

Free returns are available worldwide. If your item is eligible for return, you have 30 days from the date you receive your order to follow this procedure.

See delivery and returns for more information.